Physician profile
John Burress
NPI 1649295973
$1,564.43
in general payments reported to CMS, 2019-2025
29 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $49.20 · 2020: $12.68 · 2021: $163 · 2022: $260 · 2023: $305 · 2024: $301 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,080.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,080.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sonex Health, INC. | $174.14 | 2025 | Sx-One Microknife |
| Avanos Medical | $130.01 | 2022-2025 | Genvisc 850 Sodium Hyaluronate |
| Exact Sciences Corporation | $123.26 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $118.39 | 2021-2023 | Shingrix, Trelegy Ellipta |
| Organogenesis INC. | $117.52 | 2021-2023 | Puraply |
| Boston Scientific Corporation | $87.08 | 2022-2025 | Varithena Administration Pack, General - Pain Management |
| Medtronic, INC. | $70.27 | 2021-2024 | Venaseal |
| Astrazeneca Pharmaceuticals Lp | $62.90 | 2021 | |
| Bard Peripheral Vascular, INC. | $55.28 | 2022-2024 | Venclose Maven Catheter |
| Smith+Nephew, INC. | $53.47 | 2022-2023 | Collagenase Santyl |
| Ferring Pharmaceuticals INC. | $52.96 | 2023-2024 | Euflexxa |
| Bioventus LLC | $52.62 | 2024-2025 | Gelsyn-3, Supartz Fx Sodium Hyaluronate |
| Sumitomo Pharma America, INC. | $50.55 | 2023-2024 | Gemtesa |
| Amgen INC. | $46.73 | 2024-2025 | Krystexxa, Repatha, Otezla |
| Idorsia Pharmaceuticals US INC | $43.32 | 2023 | Quviviq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $40.70 | 2025 | Ozempic, Wegovy |
| Novartis Pharmaceuticals Corporation | $37.34 | 2022 | |
| Fidia Pharma USA INC. | $36.65 | 2024-2025 | Triluron, Hymovis |
| Cardiva Medical, INC. | $34.63 | 2025 | Optowire |
| Cgg Medical INC | $26.51 | 2024 | |
| Abbott Laboratories | $25.00 | 2022 | |
| Biocompatibles, INC. | $22.81 | 2019 | |
| Depuy Synthes Sales INC. | $16.79 | 2024 | Monovisc, Orthovisc |
| Lilly USA, LLC | $16.38 | 2025 | Mounjaro |
| Watermark Medical, INC. | $16.00 | 2024 | |
| Pfizer INC. | $14.05 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $13.40 | 2019 | |
| Medtronic Vascular, INC. | $12.99 | 2019 | |
| Abbvie INC. | $12.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Burress listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.